Derycz Scientific Hires AstraZeneca Executive to Drive Global Sales Growth

SANTA MONICA, Calif., May 31, 2011 /PRNewswire/ -- Derycz Scientific, Inc., (OTC BB: DYSC), a company pioneering a fresh way of facilitating information flow from content publishers to enterprise customers and their constituents, today announced the appointment of Armand Brevig as Global Sales Director with responsibility for customer retention, new customer acquisition, and sales distribution channels. Mr. Brevig will be based in the United Kingdom and report to Chief Executive Officer (CEO) Peter Derycz, who previously managed the company's sales activities and will continue serving as the company's Chairman and CEO.

"Armand is an expert within the Information Services and Pharmaceutical industries, possessing a keen understanding of customer needs as a result of his unique experiences working in influential positions on both the buyer and supplier side of the business," said Derycz. "As the company's first ever Global Sales Director, Armand will have an immediate impact on our global sales capabilities, strategic planning, and innovation, and will be tasked with doubling our sales force."

Mr. Brevig was most recently the Global (Content Procurement) Category Leader at AstraZeneca, which reported $33.27 billion in 2010 annual revenues. In this position, Mr. Brevig led the creation of the first global Strategic Information Services Sourcing group, led a global multimillion-dollar cross-cultural reprint (scientific journal articles) project, and influenced business process outsourcing (BPO) strategies.

Prior to his most recent position at AstraZeneca, Mr. Brevig was Global Lead (Information) Buyer at AstraZeneca.  He has also worked as a Senior Supplier Account Manager (Market Data Acquisition) at Thomson Financial, Supplier Account Manager (Market Data) at Thomson Financial, Programme Officer (Stationed in Zambia) at United Nations Industrial Development Organization, and Acting UNIDO Office Manager (Zambia) at United Nations Industrial Development Organization.  Mr. Brevig is fluent in French, German, Danish and English.

For more information about Derycz Scientific, visit www.deryczscientific.com.    

About Derycz Scientific®

Derycz Scientific, Inc. develops companies, products, services and systems that facilitate the re-use of published content in a manner that helps organizations achieve their marketing, communication and research goals effectively and in compliance with copyright law and regulatory rules.  Its subsidiary companies include Reprints Desk, Inc., Pools Press, Inc. and the newly acquired Techniques Appliquees aux Arts Graphiques, S.p.A. (TAAG).  Reprints Desk offers a one-stop solution for reprints, ePrints and single articles, and has delivered millions of articles worldwide.  Reprints Desk is an innovator in content retrieval and ePrint delivery, with services designed to help make effective use of published articles in a copyright-compliant manner.  Pools Press has excelled in the reprint market for more than 30 years.  It provides professionally printed articles from medical and technical journals; prints booklets, catalogs, pamphlets, direct mail pieces and newsletters; and works with publishers who wish to outsource a portion of or all of their reprints business.  TAAG offers printing, distribution and information logistics services, with core competencies in the professional production and distribution of clinical trial kits and clinical article reprints for the life sciences industry.  For more information, please visit www.deryczscientific.com.

Forward-Looking Statements

Certain matters discussed in this press release may be forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995.  Such matters involve risks and uncertainties that may cause actual results to differ materially, including the following: changes in economic conditions; general competitive factors; acceptance of the Company's products in the market; the Company's success in obtaining new customers; the Company's success in technology and product development; the Company's ability to execute its business model and strategic plans; the Company's success in integrating acquired entities and assets, and all the risks and related information described from time to time in the Company's filings with the Securities and Exchange Commission ("SEC"), including the financial statements and related information contained in the Company's Annual Report on Form 10-K.  The Company assumes no obligation to update the cautionary information in this release.

SOURCE Derycz Scientific, Inc.